As Mnk1/2-eIF4E signaling is implicated in cancer development, progression, metastasis and drug-resistance, we therefore sought to determine the effects of Gal and two lead NGGAs AR/AR-V7 and Mnk1/2 degraders, VNPP414 and VNPP433-3β (Figure 1) in several drug-naïve and drug/castration-resistant prostate cancer cell lines and xenografts. The gene discussed is GAL; the disease is prostate cancer.